For patients with metachronous low burden mCSPC on conventional imaging being recommended for systemic therapy, 51% responded ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Xin Gao discussing lead-in phase results of the ARAMON trial assessing darolutamide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback